From a clinical point of view, we expect that cytotoxicity will be mostly confined to EGFR-overexpressing tumor cells, similarly to what happens for most therapeutic agents against targets preferentially but not exclusively expressed in tumors. The gene discussed is EGFR; the disease is neoplasm.